Sanofi has received two separate bids for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion ...

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

The companies will use the funds to fill vials and pre-filled syringes with stockpiled vaccine ingredients, aimed at raising ...

Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. The ...

Sanofi’s Dupixent has been cleared for a chronic lung disorder in the US, in another milestone for the blockbuster drug after ...

Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease. The FDA approved the drug in 2022. Administered as chronic IV treatment. Enjaymo generated ...

The blockbuster Sanofi and Regeneron Pharmaceuticals drug Dupixent, already commercialized in several skin and lung disorders, has expanded its FDA-approval to chronic obstructive pulmonary ...

As part of the agreement, GSK, Sanofi, and CSL will produce extra bulk vaccine components tailored to the circulating strains of avian influenza. Also Read: Medicare Drug Price Negotiation Program ...

(Bloomberg) -- Sanofi has received binding offers for its consumer health division from private equity firms Clayton Dubilier ...

(RTTNews) - Sanofi (SNYNF), RadioMedix, and Orano Med have announced a licensing agreement for a next-generation radioligand medicine targeting rare cancers. The collaboration between the ...